Soleno Therapeutics to be Acquired by Neurocrine Biosciences for $2.9 Billion in All-Cash Deal
SLNO sits 78% above its 52-week low of $29.43 on elevated volume (2.1× avg).
Summary
Neurocrine Biosciences will acquire Soleno Therapeutics for $53.00 per share in cash, totaling $2.9 billion, marking a significant premium for Soleno shareholders and integrating its key drug, VYKAT XR, into Neurocrine's portfolio.
Key Events · M&A and Partnerships · SLNO
-
Definitive Acquisition Agreement
Neurocrine Biosciences has entered into a definitive agreement to acquire Soleno Therapeutics.
-
All-Cash Tender Offer
Neurocrine will acquire all outstanding shares of Soleno for $53.00 per share in cash.
-
Total Equity Value
The transaction represents a total equity value of approximately $2.9 billion.
-
Significant Premium
The offer price reflects a 34% premium to Soleno's closing share price on April 2, 2026.
Analysis · SLNO · Life Sciences
Neurocrine Biosciences has entered into a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in an all-cash tender offer, valuing Soleno's equity at approximately $2.9 billion. This represents a significant premium for Soleno shareholders, with the offer price being 34% higher than Soleno's closing share price on April 2, 2026. The acquisition, which was unanimously approved by both companies' boards, will integrate Soleno's VYKAT XR, a recently FDA-approved therapy for hyperphagia in Prader-Willi syndrome, into Neurocrine's portfolio. This transaction is expected to close within 90 days, subject to customary closing conditions, including the tender of a majority of outstanding shares and regulatory approvals. The deal is not subject to a financing condition, as Neurocrine plans to fund it with cash on hand and modest debt. This acquisition fundamentally alters Soleno's future as an independent entity, providing a clear exit for shareholders at a substantial premium.
At the time of this filing, SLNO was trading at $52.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $29.43 to $90.32. This filing was assessed with positive market sentiment and an importance score of 10 out of 10.